How AI Is Finding Its Way into Unexpected Places in Biopharma Companies
When people think of the potential for artificial intelligence to impact the biopharmaceutical industry, the focus is usually on drug discovery or in the clinic to help guide decision making with regards to pairing the right drug to the right patient. Yseop is focused on a more mundane use for the technology—the writing of clinical data reports. The company had been working in the financial services industry when it was approached by Sanofi to see if it could apply its natural language generation to make the creation of these reports faster and less expensive. We spoke to Emmanuel Walckenaer, CEO of Yseop, about artificial intelligence, its potential to change the way biopharmaceutical companies work in non-obvious ways, and why a large number of biopharmaceutical companies are turning AI to do more with less.
Student
1 年Generative AI will create a "profound technological revolution," but I think from an enterprise perspective, this generation of LLMs are nothing but cute gimmicks. Enterprises need 100% accuracy and industry-specific ontologies. Those are table stakes. Today's #LLMs lack accuracy and appropriate ontologies. Yseop is a more evolved #GenerativeAI solution. Yseop uses a hybrid approach utilizing deterministic AI (for 100% accuracy and industry-specific vocabulary) combined with LLMs like #GPT3. Customers include (typically from regulated industries): Big financial institutions (HSBC BNP Paribas , Allianz , Oracle et al); and Big Pharma (Sanofi Eli Lilly and Company and Company, L'Oréal et al). In fact, more than half of the world's top 25 Pharma companies already use Yseop to help expedite the process of writing FDA applications from #phase3 have trimmed 4+ weeks from this process (and each day is worth US$3-5M).